Evidence map›Paper›PMID 32405245›Full record

ArticleJournal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy2020

Clinical course of 2019 novel coronavirus disease (COVID-19) in individuals present during the outbreak on the Diamond Princess cruise ship.

Hideaki Kato, Hiroyuki Shimizu, Yasushi Shibue, Tomohiro Hosoda, Keisuke Iwabuchi, Kotaro Nagamine, Hiroki Saito, Reimin Sawada, Takayuki Oishi, Jun Tsukiji and 29 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 7 pooled it
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 7 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Systematic Review on Outbreaks of SARS-CoV-2 on Cruise, Navy and Cargo Ships.International journal of environmental research and public health · 2021
    Pooled it
  3. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2021
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Article
  9. COVID-19 outbreaks on ships: Analysis of three representative cases.Public health in practice (Oxford, England) · 2022
    Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Observational
  16. Article
  17. Article
  18. HIV/SARS-CoV-2 coinfection: A global perspective.Journal of medical virology · 2021
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors at 11 institutions in 1 country.

Hideaki KatoInfection Prevention and Control Department, Yokohama City University Hospital, Japan; Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Japan. Electronic address: ekato@yokohama-cu.ac.jp.
Hiroyuki ShimizuDepartment of Clinical Laboratory Medicine, Fujisawa City Hospital, Japan.
Yasushi ShibueDepartment of Infectious Diseases, Yokohama City Minato Red Cross Hospital, Japan.
Tomohiro HosodaDepartment of Infectious Diseases, Kawasaki Municipal Kawasaki Hospital, Japan.
Keisuke IwabuchiDepartment of General Medicine, Kanagawa Prefectural Ashigarakami Hospital, Japan.
Kotaro NagamineDepartment of Surgery, Yokosuka City Hospital, Japan.
Hiroki SaitoDepartment of Emergency and Critical Care Medicine, St. Marianna University School of Medicine, Yokohama City Seibu Hospital, Japan.
Reimin SawadaDepartment of Cardiology, Japanese Red Cross Hadano Hospital, Japan.
Takayuki OishiDepartment of Infection Control and Prevention, Saiseikai Yokohamashi Tobu Hospital, Japan.
Jun TsukijiDepartment of Prevention and Infection Control, Yokohama City University Medical Center, Japan.
Hiroyuki FujitaInfection Control Committee, Saiseikai Yokohama Nanbu Hospital, Japan.
Ryosuke FuruyaDepartment of Critical Care and Emergency Medicine, National Hospital Organization Yokohama Medical Center, Japan.
Makoto MasudaDepartment of Respiratory Medicine, Fujisawa City Hospital, Japan.
Osamu AkasakaEmergency Medical Center, Fujisawa City Hospital, Japan.
Yu IkedaEmergency Medical Center, Fujisawa City Hospital, Japan.
Mitsuo SakamotoDepartment of Infectious Diseases, Kawasaki Municipal Kawasaki Hospital, Japan.
Kazuya SakaiDepartment of Emergency Medicine, Yokohama City University School of Medicine, Japan.
Munehito UchiyamaDepartment of Emergency Medicine, Yokohama City University School of Medicine, Japan.
Hiroki WatanabeDepartment of Pulmonology, Yokohama City University Graduate School of Medicine, Japan.
Nobuhiro YamaguchiDepartment of Respiratory Medicine, Yokosuka City Hospital, Japan.
Ryoko HigaDepartment of Prevention and Infection Control, Yokohama City University Medical Center, Japan.
Akiko SasakiNursing Department, Japanese Red Cross Hadano Hospital, Japan.
Katsuaki TanakaDepartment of Gastroenterology, Japanese Red Cross Hadano Hospital, Japan.
Yukitoshi ToyodaDepartment of Emergency and Critical Care Medicine Major Trauma Center Trauma & Acute Care Surgery, Saiseikai Yokohamashi Tobu Hospital, Japan.
Shinsuke HamanakaDepartment of Pulmonary Medicine, Saiseikai Yokohamashi Tobu Hospital, Japan.
Naoki MiyazawaDepartment of Respiratory Medicine, Saiseikai Yokohama Nanbu Hospital, Japan.
Atsuko ShimizuInfection Control Team, National Yokohama Medical Center, Japan.
Fumie FukaseInfection Control Team, National Yokohama Medical Center, Japan.
Shunsuke IwaiDepartment of Emergency and Critical Care Medicine, St. Marianna University School of Medicine, Yokohama City Seibu Hospital, Japan.
Yuko KomaseDepartment of Respiratory Internal Medicine, St. Marianna University School of Medicine, Yokohama City Seibu Hospital, Japan.
Tsutomu KawasakiDepartment of Respiratory Medicine, Yokohama City Minato Red Cross Hospital, Japan.
Isao NagataIntensive Care Unit, Yokohama City Minato Red Cross Hospital, Japan.
Yusuke NakayamaEmergency Department, Yokohama City Minato Red Cross Hospital, Japan.
Tetsuhiro TakeiIntensive Care Unit, Yokohama City Minato Red Cross Hospital, Japan.
Katsuo KimuraDepartment of Neurology, Yokohama City University Medical Center, Japan.
Reiko KunisakiInflammatory Bowel Disease Center, Yokohama City University Medical Center, Japan.
Makoto KudoRespiratory Disease Center, Yokohama City University Medical Center, Japan.
Ichiro TakeuchiKanagawa Disaster Medical Assistance Team, Japan; Advanced Emergency Medical Service Center, Yokohama City University Medical Center, Japan.
Hideaki NakajimaDepartment of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Japan.
Yokohama City University Medical Center · JPYokohama Municipal Minato Red Cross Hospital · JPFujisawa City Hospital · JPYokohama City University · JPJapanese Red Cross Hadano Hospital · JPSt. Marianna University School of Medicine · JPHiratsuka City Hospital · JPKawasaki Hospital · JPSaiseikai Ibaraki Hospital · JPNational Hospital Organization · JPYokohama City University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the clinical course of individuals with 2019 novel coronavirus disease (COVID-19) who were transferred from the Diamond Princess cruise ship to 12 local hospitals. The conditions and clinical courses of patients with pneumonia were compared with those of patients without pneumonia. Among 70 patients (median age: 67 years) analyzed, the major symptoms were fever (64.3%), cough (54.3%), and general fatigue (24.3%). Forty-three patients (61.4%) had pneumonia. Higher body temperature, heart rate, and respiratory rate as well as higher of lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and C-reactive protein (CRP) levels and lower serum albumin level and lymphocyte count were associated with the presence of pneumonia. Ground-glass opacity was found in 97.7% of the patients with pneumonia. Patients were administered neuraminidase inhibitors (20%), lopinavir/ritonavir (32.9%), and ciclesonide inhalation (11.4%). Mechanical ventilation and veno-venous extracorporeal membrane oxygenation was performed on 14 (20%) and 2 (2.9%) patients, respectively; two patients died. The median duration of intubation was 12 days. The patients with COVID-19 transferred to local hospitals during the outbreak had severe conditions and needed close monitoring. The severity of COVID-19 depends on the presence of pneumonia. High serum LDH, AST and CRP levels and low serum albumin level and lymphocyte count were found to be predictors of pneumonia. It was challenging for local hospitals to admit and treat these patients during the outbreak of COVID-19. Assessment of severity was crucial to manage a large number of patients.

Indexed as

BetacoronavirusDisease OutbreaksAgedCoronavirus InfectionsCOVID-19Diabetes ComplicationsFemaleHumansHypertensionJapanMaleMiddle AgedPandemicsPatient AcuityPneumonia, ViralPrognosisCoronavirusCOVID-19Diamond Princess cruise shipOutbreakSARS-CoV-2

Identifiers

PMID32405245
PMCPMC7218347
OpenAlexW3024879327

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.